SEAGEN INC. 
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Chris Boshoff
PSD | President | - | Dec. 13 |
Karin Tollefson
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
William Compton
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | Dec. 13 | |
Deborah Baron
BRD | Director/Board Member | 55 | Dec. 13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.99% | 215 M€ | +10.80% | - | |
| 2.68% | 1 M€ | -4.80% | - | |
| 2.53% | 0 M€ | 0.00% | - | |
| 2.25% | 0 M€ | 0.00% | - |
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit :
- ventes de produits (87%) ;
- royalties (8,4%) ;
- revenus issus d'accords de collaboration et de licence (4,6%).
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +25.69% | 47.9B | |
| +47.19% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |